Anavex Life Sciences Corp (NASDAQ:AVXL)
| 19.25 BATS BZX Real-Time Price As of 3:32pm ET |  +1.61 / +9.13%Today’s Change | 3.75 Today|||52-Week Range 31.50 | +256.48% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.3B |
Company Description
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Contact Information
Anavex Life Sciences Corp. 51 West 52nd Street New York New York 10019-6163 |
Employees
Shareholders
| Individual stakeholders | 3.10% |
| Mutual fund holders | 16.87% |
| Other institutional | 12.00% |
Top Executives
| Christopher U. Missling | Chairman, President, CEO & Secretary |
| Stephan Toutain | Chief Operating Officer |
| Sandra Boenisch | Principal Financial Officer & Treasurer |
| Walter E. Kaufmann | Chief Medical Officer |
| Daniel Klamer | VP-Business Development & Scientific Strategy |
